Focal Adhesion Kinase as a Therapeutic Target of Bortezomib

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 10, 2010, Pages 747-752

  Ko, Bor Sheng ^a,b   Chang, Tzu Ching ^a   Liou, Jun Yang ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Bortezomib; Cancer treatment; Focal adhesion kinase; Nf b; P53; Proteasome inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CARBOPLATIN; DOCETAXEL; EPOXOMYCIN; FOCAL ADHESION KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEMETREXED; PROTEASOME INHIBITOR; PROTEIN KINASE B; PROTEIN P53; SORAFENIB; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; HUMAN; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MANTLE CELL LYMPHOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE MYELOMA; MYELOMA; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 79952752797     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152010794728666     Document Type: Article

References (82)

1. McLean, G. W.; Carragher, N. O.; Avizienyte, E.; Evans, J.; Brunton, V. G.; Frame, M. C. The role of focal-adhesion kinase in cancer-a new therapeutic opportunity. Nat. Rev. Cancer, 2005, 5(7), 505-515.
2. van Nimwegen, M. J.; van de Water, B. Focal adhesion kinase: a potential target in cancer therapy. Biochem. Pharmacol., 2007, 73(5), 597-609.
3. Wozniak, M. A.; Modzelewska, K.; Kwong, L.; Keely, P. J. Focal adhesion regulation of cell behavior. Biochim. Biophys. Acta, 2004, 1692(2-3), 103-119.
4. Kornberg, L.; Earp, H. S.; Parsons, J. T.; Schaller, M.; Juliano, R. L. Cell adhesion or integrin clustering increases phosphorylation of a focal adhesion-associated tyrosine kinase. J. Biol. Chem., 1992, 267(33), 23439-23442.
5. Sieg, D. J.; Hauck, C. R.; Ilic, D.; Klingbeil, C. K.; Schaefer, E.; Damsky, C. H.; Schlaepfer, D. D. FAK integrates growth-factor and integrin signals to promote cell migration. Nat. Cell Biol., 2000, 2(5), 249-256.
6. Clark, E. A.; Brugge, J. S. Integrins and signal transduction pathways: the road taken. Science, 1995, 268(5208), 233-239.
7. Xu, L. H.; Owens, L. V.; Sturge, G. C.; Yang, X.; Liu, E. T.; Craven, R. J.; Cance, W. G. Attenuation of the expression of the focal adhesion kinase induces apoptosis in tumor cells. Cell Growth Differ., 1996, 7(4), 413-418.
8. Han, N. M.; Fleming, R. Y.; Curley, S. A.; Gallick, G. E. Overexpression of focal adhesion kinase (p125FAK) in human colorectal carcinoma liver metastases: independence from c-src or c-yes activation. Ann. Surg. Oncol., 1997, 4(3), 264-268.
9. Cance, W. G.; Harris, J. E.; Iacocca, M. V.; Roche, E.; Yang, X.; Chang, J.; Simkins, S.; Xu, L. Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes. Clin. Cancer Res., 2000, 6(6), 2417-2423.
10. Owens, L. V.; Xu, L.; Craven, R. J.; Dent, G. A.; Weiner, T. M.; Kornberg, L.; Liu, E. T.; Cance, W. G. Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res., 1995, 55(13), 2752-2755.
11. McCormack, S. J.; Brazinski, S. E.; Moore, J. L., Jr.; Werness, B. A.; Goldstein, D. J. Activation of the focal adhesion kinase signal transduction pathway in cervical carcinoma cell lines and human genital epithelial cells immortalized with human papillomavirus type 18. Oncogene, 1997, 15(3), 265-274.
12. Tremblay, L.; Hauck, W.; Aprikian, A. G.; Begin, L. R.; Chapdelaine, A.; Chevalier, S. Focal adhesion kinase (pp125FAK) expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma. Int. J. Cancer, 1996, 68(2), 164-171.
13. Owens, L. V.; Xu, L.; Dent, G. A.; Yang, X.; Sturge, G. C.; Craven, R. J.; Cance, W. G. Focal adhesion kinase as a marker of invasive potential in differentiated human thyroid cancer. Ann. Surg. Oncol., 1996, 3(1), 100-105.
14. Beierle, E. A.; Massoll, N. A.; Hartwich, J.; Kurenova, E. V.; Golubovskaya, V. M.; Cance, W. G.; McGrady, P.; London, W. B. Focal adhesion kinase expression in human neuroblastoma: immunohistochemical and real-time PCR analyses. Clin. Cancer Res., 2008, 14(11), 3299-3305.
15. Fujii, T.; Koshikawa, K.; Nomoto, S.; Okochi, O.; Kaneko, T.; Inoue, S.; Yatabe, Y.; Takeda, S.; Nakao, A. Focal adhesion kinase is overexpressed in hepatocellular carcinoma and can be served as an independent prognostic factor. J. Hepatol., 2004, 41(1), 104-111.
16. Itoh, S.; Maeda, T.; Shimada, M.; Aishima, S.; Shirabe, K.; Tanaka, S.; Maehara, Y. Role of expression of focal adhesion kinase in progression of hepatocellular carcinoma. Clin. Cancer Res., 2004, 10(8), 2812-2817.
17. Jan, Y. J.; Ko, B. S.; Hsu, C.; Chang, T. C.; Chen, S. C.; Wang, J.; Liou, J. Y. Overexpressed focal adhesion kinase predicts a higher incidence of extrahepatic metastasis and worse survival in hepatocellular carcinoma. Hum. Pathol., 2009, 40(10), 1384-1390.
18. Judson, P. L.; He, X.; Cance, W. G.; Van Le, L. Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma. Cancer, 1999, 86(8), 1551-1556.
19. Miyazaki, T.; Kato, H.; Nakajima, M.; Sohda, M.; Fukai, Y.; Masuda, N.; Manda, R.; Fukuchi, M.; Tsukada, K.; Kuwano, H. FAK overexpression is correlated with tumour invasiveness and lymph node metastasis in oesophageal squamous cell carcinoma. Br. J. Cancer, 2003, 89(1), 140-145.
20. Yuan, Z.; Zheng, Q.; Fan, J.; Ai, K. X.; Chen, J.; Huang, X. Y. Expression and prognostic significance of focal adhesion kinase in hepatocellular carcinoma. J. Cancer Res. Clin. Oncol., 2010, 136(10), 1489-1496.
21. Lai, I. R.; Chu, P. Y.; Lin, H. S.; Liou, J. Y.; Jan, Y. J.; Lee, J. C.; Shen, T. L. Phosphorylation of focal adhesion kinase at Tyr397 in gastric carcinomas and its clinical significance. Am. J. Pathol., 2010, 177(4), 1629-1637.
22. Chen, J. S.; Huang, X. H.; Wang, Q.; Chen, X. L.; Fu, X. H.; Tan, H. X.; Zhang, L. J.; Li, W.; Bi, J. FAK is involved in invasion and metastasis of hepatocellular carcinoma. Clin. Exp. Metastasis, 2010, 27(2), 71-82.
23. Golubovskaya, V.; Kaur, A.; Cance, W. Cloning and characterization of the promoter region of human focal adhesion kinase gene: nuclear factor kappa B and p53 binding sites. Biochim. Biophys. Acta, 2004, 1678(2-3), 111-125.
24. Gilmore, T. D. Multiple myeloma: lusting for NF-kappaB. Cancer Cell, 2007, 12(2), 95-97.
25. Corsi, J. M.; Rouer, E.; Girault, J. A.; Enslen, H. Organization and post-transcriptional processing of focal adhesion kinase gene. BMC Genomics, 2006, 7, 198.
26. Perkins, N. D. Integrating cell-signalling pathways with NFkappaB and IKK function. Nat. Rev. Mol. Cell Biol., 2007, 8(1), 49-62.
27. Ko, B. S.; Chang, T. C.; Chen, C. H.; Liu, C. C.; Kuo, C. C.; Hsu, C.; Shen, Y. C.; Shen, T. L.; Golubovskaya, V. M.; Chang, C. C.; Shyue, S. K.; Liou, J. Y. Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B. Life Sci., 2010, 86(5-6), 199-206.
28. Anaganti, S.; Fernandez-Cuesta, L.; Langerod, A.; Hainaut, P.; Olivier, M. p53-Dependent repression of focal adhesion kinase in response to estradiol in breast cancer cell-lines. Cancer Lett., 2011, 300(2), 215-224.
29. Golubovskaya, V. M.; Finch, R.; Kweh, F.; Massoll, N. A.; Campbell-Thompson, M.; Wallace, M. R.; Cance, W. G. p53 regulates FAK expression in human tumor cells. Mol. Carcinog., 2008, 47(5), 373-382.
30. Escarcega, R. O.; Fuentes-Alexandro, S.; Garcia-Carrasco, M.; Gatica, A.; Zamora, A. The transcription factor nuclear factorkappa B and cancer. Clin. Oncol. (R Coll Radiol), 2007, 19(2), 154-161.
31. Hollstein, M.; Sidransky, D.; Vogelstein, B.; Harris, C. C. p53 mutations in human cancers. Science, 1991, 253(5015), 49-53.
32. Schwartz, A. L.; Ciechanover, A. The ubiquitin-proteasome pathway and pathogenesis of human diseases. Annu. Rev. Med., 1999, 50(57-74.
33. Moore, B. S.; Eustaquio, A. S.; McGlinchey, R. P. Advances in and applications of proteasome inhibitors. Curr. Opin. Chem. Biol., 2008, 12(4), 434-440.
34. Groll, M.; Ditzel, L.; Lowe, J.; Stock, D.; Bochtler, M.; Bartunik, H. D.; Huber, R. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature, 1997, 386(6624), 463-471.
35. Myung, J.; Kim, K. B.; Lindsten, K.; Dantuma, N. P.; Crews, C. M. Lack of proteasome active site allostery as revealed by subunitspecific inhibitors. Mol. Cell, 2001, 7(2), 411-420.
36. Borissenko, L.; Groll, M. 20S proteasome and its inhibitors: crystallographic knowledge for drug development. Chem. Rev., 2007, 107(3), 687-717.
37. Kisselev, A. F.; Goldberg, A. L. Proteasome inhibitors: from research tools to drug candidates. Chem. Biol., 2001, 8(8), 739-758.
38. Dick, L. R.; Cruikshank, A. A.; Grenier, L.; Melandri, F. D.; Nunes, S. L.; Stein, R. L. Mechanistic studies on the inactivation of the proteasome by lactacystin: a central role for clasto-lactacystin beta-lactone. J. Biol. Chem., 1996, 271(13), 7273-7276.
39. Meng, L.; Mohan, R.; Kwok, B. H.; Elofsson, M.; Sin, N.; Crews, C. M. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc. Natl. Acad. Sci. USA, 1999, 96(18), 10403-10408.
40. Bowerman, B.; Kurz, T. Degrade to create: developmental requirements for ubiquitin-mediated proteolysis during early C. elegans embryogenesis. Development, 2006, 133(5), 773-784.
41. Elliott, P. J.; Zollner, T. M.; Boehncke, W. H. Proteasome inhibition: a new anti-inflammatory strategy. J. Mol. Med., 2003, 81(4), 235-245.
42. Muratani, M.; Tansey, W. P. How the ubiquitin-proteasome system controls transcription. Nat. Rev. Mol. Cell Biol., 2003, 4(3), 192-201.
43. Wojcikiewicz, R. J. Regulated ubiquitination of proteins in GPCRinitiated signaling pathways. Trends Pharmacol. Sci., 2004, 25(1), 35-41.
44. Meiners, S.; Ludwig, A.; Stangl, V.; Stangl, K. Proteasome inhibitors: poisons and remedies. Med. Res. Rev., 2008, 28(2), 309-327.
45. Maki, C. G.; Huibregtse, J. M.; Howley, P. M. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res., 1996, 56(11), 2649-2654.
46. Pagano, M.; Tam, S. W.; Theodoras, A. M.; Beer-Romero, P.; Del Sal, G.; Chau, V.; Yew, P. R.; Draetta, G. F.; Rolfe, M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin dependent kinase inhibitor p27. Science, 1995, 269(5224), 682-685.
47. Green, D. R.; Kroemer, G. The pathophysiology of mitochondrial cell death. Science, 2004, 305(5684), 626-629.
48. Wu, W. K.; Sung, J. J.; Wu, Y. C.; Li, Z. J.; Yu, L.; Cho, C. H. Bone morphogenetic protein signalling is required for the antimitogenic effect of the proteasome inhibitor MG-132 on colon cancer cells. Br. J. Pharmacol., 2008, 154(3), 632-638.
49. Miller, C. P.; Rudra, S.; Keating, M. J.; Wierda, W. G.; Palladino, M.; Chandra, J. Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells. Blood, 2009, 113(18), 4289-4299.
50. Orlowski, R. Z.; Kuhn, D. J. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin. Cancer Res., 2008, 14(6), 1649-1657.
51. Shah, J. J.; Orlowski, R. Z. Proteasome inhibitors in the treatment of multiple myeloma. Leukemia, 2009, 23(11), 1964-1979.
52. Blade, J.; Sonneveld, P.; San Miguel, J. F.; Sutherland, H. J.; Hajek, R.; Nagler, A.; Spencer, A.; Robak, T.; Cibeira, M. T.; Zhuang, S. H.; Harousseau, J. L.; Orlowski, R. Z. Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. Clin. Lymphoma Myeloma, 2008, 8(6), 352-355.
53. Mikhael, J. R.; Belch, A. R.; Prince, H. M.; Lucio, M. N.; Maiolino, A.; Corso, A.; Petrucci, M. T.; Musto, P.; Komarnicki, M.; Stewart, A. K. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br. J. Haematol., 2009, 144(2), 169-175.
54. Cavo, M.; Tacchetti, P.; Patriarca, F.; Petrucci, M. T.; Pantani, L.; Galli, M.; Di Raimondo, F.; Crippa, C.; Zamagni, E.; Palumbo, A.; Offidani, M.; Corradini, P.; Narni, F.; Spadano, A.; Pescosta, N.; Deliliers, G. L.; Ledda, A.; Cellini, C.; Caravita, T.; Tosi, P.; Baccarani, M. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet, 2010, 376(9758), 2075-2085.
55. Harousseau, J. L.; Palumbo, A.; Richardson, P. G.; Schlag, R.; Dimopoulos, M. A.; Shpilberg, O.; Kropff, M.; Kentos, A.; Cavo, M.; Golenkov, A.; Komarnicki, M.; Mateos, M. V.; Esseltine, D. L.; Cakana, A.; Liu, K.; Deraedt, W.; van de Velde, H.; San Miguel, J. F. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalanprednisone. Blood, 2010, 116(19), 3743-3750.
56. San Miguel, J. F.; Schlag, R.; Khuageva, N. K.; Dimopoulos, M. A.; Shpilberg, O.; Kropff, M.; Spicka, I.; Petrucci, M. T.; Palumbo, A.; Samoilova, O. S.; Dmoszynska, A.; Abdulkadyrov, K. M.; Schots, R.; Jiang, B.; Mateos, M. V.; Anderson, K. C.; Esseltine, D. L.; Liu, K.; Cakana, A.; van de Velde, H.; Richardson, P. G. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med., 2008, 359(9), 906-917.
57. Dimopoulos, M. A.; Richardson, P. G.; Schlag, R.; Khuageva, N. K.; Shpilberg, O.; Kastritis, E.; Kropff, M.; Petrucci, M. T.; Delforge, M.; Alexeeva, J.; Schots, R.; Masszi, T.; Mateos, M. V.; Deraedt, W.; Liu, K.; Cakana, A.; van de Velde, H.; San Miguel, J. F. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J. Clin. Oncol., 2009, 27(36), 6086-6093.
58. Rummel, M. J.; de Vos, S.; Hoelzer, D.; Koeffler, H. P.; Hofmann, W. K. Altered apoptosis pathways in mantle cell lymphoma. Leuk Lymphoma, 2004, 45(1), 49-54.
59. Marshansky, V.; Wang, X.; Bertrand, R.; Luo, H.; Duguid, W.; Chinnadurai, G.; Kanaan, N.; Vu, M. D.; Wu, J. Proteasomes modulate balance among proapoptotic and antiapoptotic Bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells. J. Immunol., 2001, 166(5), 3130-3142.
60. Belch, A.; Kouroukis, C. T.; Crump, M.; Sehn, L.; Gascoyne, R. D.; Klasa, R.; Powers, J.; Wright, J.; Eisenhauer, E. A. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann. Oncol., 2007, 18(1), 116-121.
61. Fisher, R. I.; Bernstein, S. H.; Kahl, B. S.; Djulbegovic, B.; Robertson, M. J.; de Vos, S.; Epner, E.; Krishnan, A.; Leonard, J. P.; Lonial, S.; Stadtmauer, E. A.; O'Connor, O. A.; Shi, H.; Boral, A. L.; Goy, A. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J. Clin. Oncol., 2006, 24(30), 4867-4874.
62. Aghajanian, C.; Soignet, S.; Dizon, D. S.; Pien, C. S.; Adams, J.; Elliott, P. J.; Sabbatini, P.; Miller, V.; Hensley, M. L.; Pezzulli, S.; Canales, C.; Daud, A.; Spriggs, D. R. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Res., 2002, 8(8), 2505-2511.
63. Fanucchi, M. P.; Fossella, F. V.; Belt, R.; Natale, R.; Fidias, P.; Carbone, D. P.; Govindan, R.; Raez, L. E.; Robert, F.; Ribeiro, M.; Akerley, W.; Kelly, K.; Limentani, S. A.; Crawford, J.; Reimers, H. J.; Axelrod, R.; Kashala, O.; Sheng, S.; Schiller, J. H. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J. Clin. Oncol., 2006, 24(31), 5025-5033.
64. Kennedy, B.; Gargoum, F.; Bystricky, B.; Curran, D. R.; O'Connor, T. M. Novel agents in the management of lung cancer. Curr. Med. Chem., 2010, 17(35), 4291-4325.
65. Papandreou, C. N.; Logothetis, C. J. Bortezomib as a potential treatment for prostate cancer. Cancer Res., 2004, 64(15), 5036-5043.
66. Papandreou, C. N.; Daliani, D. D.; Nix, D.; Yang, H.; Madden, T.; Wang, X.; Pien, C. S.; Millikan, R. E.; Tu, S. M.; Pagliaro, L.; Kim, J.; Adams, J.; Elliott, P.; Esseltine, D.; Petrusich, A.; Dieringer, P.; Perez, C.; Logothetis, C. J. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J. Clin. Oncol., 2004, 22(11), 2108-2121.
67. Dreicer, R.; Petrylak, D.; Agus, D.; Webb, I.; Roth, B. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin. Cancer Res., 2007, 13(4), 1208-1215.
68. Voutsadakis, I. A.; Papandreou, C. N. The ubiquitin-proteasome system in prostate cancer and its transition to castration resistance. Urol. Oncol., 2010, [Epub ahead of print].
69. Wu, W. K.; Cho, C. H.; Lee, C. W.; Wu, K.; Fan, D.; Yu, J.; Sung, J. J. Proteasome inhibition: a new therapeutic strategy to cancer treatment. Cancer Lett., 2010, 293(1), 15-22.
70. Calvaruso, G.; Giuliano, M.; Portanova, P.; Pellerito, O.; Vento, R.; Tesoriere, G. Hsp72 controls bortezomib-induced HepG2 cell death via interaction with pro-apoptotic factors. Oncol. Rep., 2007, 18(2), 447-450.
71. Lauricella, M.; Emanuele, S.; D'Anneo, A.; Calvaruso, G.; Vassallo, B.; Carlisi, D.; Portanova, P.; Vento, R.; Tesoriere, G. JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways. Apoptosis, 2006, 11(4), 607-625.
72. Ling, X.; Calinski, D.; Chanan-Khan, A. A.; Zhou, M.; Li, F. Cancer cell sensitivity to bortezomib is associated with surviving expression and p53 status but not cancer cell types. J. Exp. Clin. Cancer Res., 2010, 29(8), [Epub ahead of print].
73. Lioni, M.; Noma, K.; Snyder, A.; Klein-Szanto, A.; Diehl, J. A.; Rustgi, A. K.; Herlyn, M.; Smalley, K. S. Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway. Mol. Cancer Ther., 2008, 7(9), 2866-2875.
74. Morgillo, F.; D'Aiuto, E.; Troiani, T.; Martinelli, E.; Cascone, T.; De Palma, R.; Orditura, M.; De Vita, F.; Ciardiello, F. Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors. Lung Cancer, 2010, [Epub ahead of print].
75. Vaziri, S. A.; Hill, J.; Chikamori, K.; Grabowski, D. R.; Takigawa, N.; Chawla-Sarkar, M.; Rybicki, L. R.; Gudkov, A. V.; Mekhail, T.; Bukowski, R. M.; Ganapathi, M. K.; Ganapathi, R. Sensitization of DNA damage-induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3sigma and survivin. Mol. Cancer Ther., 2005, 4(12), 1880-1890.
76. Ganten, T. M.; Koschny, R.; Haas, T. L.; Sykora, J.; Li-Weber, M.; Herzer, K.; Walczak, H. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology, 2005, 42(3), 588-597.
77. Ding, J.; Huang, S.; Wu, S.; Zhao, Y.; Liang, L.; Yan, M.; Ge, C.; Yao, J.; Chen, T.; Wan, D.; Wang, H.; Gu, J.; Yao, M.; Li, J.; Tu, H.; He, X. Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA. Nat. Cell Biol., 2010, 12(4), 390-399.
78. Kim, G. P.; Mahoney, M. R.; Szydlo, D.; Mok, T. S.; Marshke, R.; Holen, K.; Picus, J.; Boyer, M.; Pitot, H. C.; Rubin, J.; Philip, P. A.; Nowak, A.; Wright, J. J.; Erlichman, C. An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. Invest. New Drugs, 2010, [Epub ahead of print].
79. Chen, K. F.; Yeh, P. Y.; Hsu, C.; Hsu, C. H.; Lu, Y. S.; Hsieh, H. P.; Chen, P. J.; Cheng, A. L. Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway. J. Biol. Chem., 2009, 284(17), 11121-11133.
80. Chen, K. F.; Yeh, P. Y.; Yeh, K. H.; Lu, Y. S.; Huang, S. Y.; Cheng, A. L. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res., 2008, 68(16), 6698-6707.
81. Chen, K. F.; Liu, C. Y.; Lin, Y. C.; Yu, H. C.; Liu, T. H.; Hou, D. R.; Chen, P. J.; Cheng, A. L. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene, 2010, 29(47), 6257-6266.
82. Chen, K. F.; Yu, H. C.; Liu, T. H.; Lee, S. S.; Chen, P. J.; Cheng, A. L. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. J. Hepatol., 2010, 52(1), 88-95